LONA catalyst calendar

LeonaBio, Inc.

Upcoming catalysts
2
Cash runway
7.3 months
Cash & investments
$51M
Phase 3 programs
3

LeonaBio, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on November 13, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 7.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 8 concluded trials, 75% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 13, 2026 est. Next quarterly earnings (projected) Earnings —
April 15, 2027 Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Trial Milestone Phase 3

Track LONA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open LONA in the tracker

Recent history

DateEventTypePhase
September 22, 2026 8-K filed: Other event Filing —
August 26, 2026 8-K filed: Other event Filing —
August 14, 2026 Quarterly results filed (8-K) Earnings —
May 7, 2026 Quarterly results filed (8-K) Earnings —
March 31, 2026 8-K/A filed: Acquisition completed Corporate —
March 26, 2026 Quarterly results filed (8-K) Earnings —
March 19, 2026 8-K filed: Leadership change, Other event Corporate —
January 9, 2026 8-K filed: Leadership change, Reg FD disclosure, Other event Corporate —
December 18, 2025 8-K filed: Material agreement, Reg FD disclosure, Other event Corporate —
December 18, 2025 8-K/A filed: Material agreement, Reg FD disclosure, Other event Corporate —
November 6, 2025 Quarterly results filed (8-K) Earnings —
October 3, 2025 8-K filed: Other event Filing —
August 7, 2025 Quarterly results filed (8-K) Earnings —
May 9, 2025 Quarterly results filed (8-K) Earnings —
April 16, 2025 8-K filed: Listing / standard notice Corporate —
November 25, 2024 A SAD and MAD Study of the Safety, Tolerability, and Pharmacokinetics of ATH-1105 Trial Milestone Phase 1
October 23, 2024 Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease Trial Milestone Phase 2/Phase 3
July 15, 2024 ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease Trial Milestone Phase 2/Phase 3
April 19, 2023 ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial) Trial Milestone Phase 2
October 18, 2022 A Study of the Absorption, Metabolism, and Excretion of [14C]-Fosgonimeton (ATH-1017) Trial Milestone Phase 1
September 9, 2022 Safety, Tolerability, and Pharmacokinetics Study of ATH-1020 Trial Milestone Phase 1
May 20, 2022 A Study of ATH-1017 in Mild to Moderate Alzheimer's Disease Trial Milestone Phase 2
September 5, 2019 Safety, Tolerability, and Pharmacokinetics Study of NDX-1017 Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.